Literature DB >> 35291531

Thrombotic Thrombocytopenic Purpura: A Tale of Two Cases.

Prakash R Ghogale1, Ashutosh Kumar Pandey2, Edavan Pulikkanath Praveen3, Prabhakar Yadav4, Saurabh Pathak4.   

Abstract

Microangiopathic hemolytic anaemia, thrombocytopenia, renal failure, neurologic abnormalities, and fever form the pentad of thrombotic thrombocytopenic purpura (TTP). Early diagnosis is crucial because TTP responds well to plasmapheresis therapy but is associated with substantial mortality if left untreated. A substantial percentage of patients with TTP used to die from systemic microvascular thrombosis in the brain and the heart. However, since plasma exchange therapy became a mainstay in the treatment of TTP, mortality has reduced considerably. Diagnosing TTP can be difficult due to the vast range of symptoms and the absence of clearly defined diagnostic criteria. Hemolytic uremic syndrome and disseminated intravascular coagulation are a close differential of TTP. Here we report two patients with TTP who achieved remission when treated with steroids, plasmapheresis and were free of disease relapse till about two months during follow-up in the outpatient department.
Copyright © 2022, Ghogale et al.

Entities:  

Keywords:  microangiopathic haemolytic anaemia; plasmapheresis; red-cell fragmentation; steroids; thrombotic thrombocytopenic purpura; ttp

Year:  2022        PMID: 35291531      PMCID: PMC8897657          DOI: 10.7759/cureus.21853

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  9 in total

Review 1.  Thrombotic microangiopathies.

Authors:  Joel L Moake
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

Review 2.  Clinical practice. Thrombotic thrombocytopenic purpura.

Authors:  James N George
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

Review 3.  Haemolytic-uraemic syndrome in practice.

Authors:  G H Neild
Journal:  Lancet       Date:  1994-02-12       Impact factor: 79.321

Review 4.  Thrombotic thrombocytopenic purpura and autoimmunity: a tale of shadows and suspects.

Authors:  C Porta; R Caporali; C Montecucco
Journal:  Haematologica       Date:  1999-03       Impact factor: 9.941

5.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

Authors:  W R Bell; H G Braine; P M Ness; T S Kickler
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

6.  Thrombotic thrombocytopenic purpura associated with clopidogrel.

Authors:  C L Bennett; J M Connors; J M Carwile; J L Moake; W R Bell; S R Tarantolo; L J McCarthy; R Sarode; A J Hatfield; M D Feldman; C J Davidson; H M Tsai
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

Review 7.  Recent advances in thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler; Joel L Moake; Toshiyuki Miyata; James N George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2004

Review 8.  The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007.

Authors:  James N George
Journal:  Kidney Int Suppl       Date:  2009-02       Impact factor: 10.545

9.  Treatment of thrombotic thrombocytopenic purpura with plasma exchange, antiplatelet agents, corticosteroid, and plasma infusion: Mayo Clinic experience.

Authors:  R L Breckenridge; L A Solberg; A A Pineda; R M Petitt; D D Dharkar
Journal:  J Clin Apher       Date:  1982       Impact factor: 2.821

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.